Tanonalla 30 mg / 15 mg Norvégia - norvég - Statens legemiddelverk

tanonalla 30 mg / 15 mg

sandoz - københavn - oksykodonhydroklorid / naloksonhydrokloriddihydrat - depottablett - 30 mg / 15 mg

Baraclude 0.5 mg Norvégia - norvég - Statens legemiddelverk

baraclude 0.5 mg

orifarm as - entekavirmonohydrat - tablett, filmdrasjert - 0.5 mg

Briviact 25 mg Norvégia - norvég - Statens legemiddelverk

briviact 25 mg

2care4 aps - brivaracetam - tablett, filmdrasjert - 25 mg

Briviact 50 mg Norvégia - norvég - Statens legemiddelverk

briviact 50 mg

2care4 aps - brivaracetam - tablett, filmdrasjert - 50 mg

Briviact 75 mg Norvégia - norvég - Statens legemiddelverk

briviact 75 mg

2care4 aps - brivaracetam - tablett, filmdrasjert - 75 mg

Briviact 100 mg Norvégia - norvég - Statens legemiddelverk

briviact 100 mg

2care4 aps - brivaracetam - tablett, filmdrasjert - 100 mg

Baraclude 0.5 mg Norvégia - norvég - Statens legemiddelverk

baraclude 0.5 mg

abacus medicine a/s - entekavirmonohydrat - tablett, filmdrasjert - 0.5 mg

Baraclude 1 mg Norvégia - norvég - Statens legemiddelverk

baraclude 1 mg

abacus medicine a/s - entekavirmonohydrat - tablett, filmdrasjert - 1 mg

Blincyto Európai Unió - norvég - EMA (European Medicines Agency)

blincyto

amgen europe b.v. - blinatumomab - forløpercellelymfoblastisk leukemi-lymfom - antineoplastiske midler - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Vitalipid Adult Norvégia - norvég - Statens legemiddelverk

vitalipid adult

fresenius kabi norge as - halden - tokoferol, helracemisk, a- / retinylpalmitat / fytomenadion / ergokalsiferol - konsentrat til infusjonsvæske, emulsjon - 910 mikrog/ ml / 99 mikrog/ ml / 15 mikrog/ ml / 0.5 mikrog/ ml